Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effects of furosemide on the hearing loss induced by impulse noise

Autor: Kriksunov Leonid, Weinberger Jeffrey M, Adelman Cahtia, Sohmer Haim

Publikováno v: Journal of Occupational Medicine and Toxicology, Vol 6, Iss 1, p 14 (2011)

Abstract Background The permanent hearing loss following exposure to intense noise can be due either to mechanical structural damage (tearing) caused directly by the noise or to metabolic (biochemical) damage resulting from the elevated levels of fre

Externí odkaz: https://doaj.org/article/e5154579aad34d099f067e9b30f15fa9

Impact of DNA damage repair alterations on prostate cancer progression and metastasis.

Autor: Lukashchuk N; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom., Barnicle A; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom., Adelman CA; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom., Armenia J; Oncology Data Science, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom., Kang J; Global Medicines Development, Oncology Research and Development (R&D), AstraZeneca, Gaithersburg, MD, United States., Barrett JC; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Waltham, MA, United States., Harrington EA; Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Jun 26; Vol. 13, pp. 1162644. Date of Electronic Publication: 2023 Jun 26 (Print Publication: 2023).

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).

Autor: Hussain M; Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Corcoran C; AstraZeneca, Cambridge, United Kingdom., Sibilla C; AstraZeneca, Cambridge, United Kingdom., Fizazi K; Institut Gustave Roussy, University of Paris Sud, Villejuif, France., Saad F; Centre Hospitalier de l'Université de Montréal/CRCHUM, Montreal, Canada., Shore N; Carolina Urologic Research Center, Myrtle Beach, South Carolina., Sandhu S; Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia., Mateo J; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona, Spain., Olmos D; Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Instituto de Investigación Biomédica de Málaga (IBIMA), Malaga, Spain., Mehra N; Radboud University Medical Center, Nijmegen, the Netherlands., Kolinsky MP; Cross Cancer Institute and University of Alberta, Edmonton, Canada., Roubaud G; Institut Bergonié, Bordeaux, France., Özgüroǧlu M; Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey., Matsubara N; National Cancer Center Hospital East, Chiba, Japan., Gedye C; Calvary Mater Newcastle, Waratah, Australia., Choi YD; Yonsei University College of Medicine, Seoul, Republic of South Korea., Padua C; Cetus Medicina Oncológica, Betim, Brazil., Kohlmann A; AstraZeneca, Gaithersburg, Maryland., Huisden R; AstraZeneca, Cambridge, United Kingdom., Elvin JA; Foundation Medicine, Inc., Cambridge, Massachusetts., Kang J; AstraZeneca, Gaithersburg, Maryland., Adelman CA; AstraZeneca, Cambridge, United Kingdom., Allen A; AstraZeneca, Cambridge, United Kingdom., Poehlein C; Merck & Co., Inc., Kenilworth, New Jersey., de Bono J; The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Apr 14; Vol. 28 (8), pp. 1518-1530.